Top

Supportive Care in Cancer

Published in:

01-06-2014 | Original Article

Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients

Authors: Darren Hunter, Richard Oates, Janet Gawthrop, Michelle Bishop, Suki Gill

Published in: Supportive Care in Cancer | Issue 6/2014

Abstract

Purpose

Information on complementary and alternative medicine (CAM) use in Australian radiotherapy patients is sparse. This study investigated the type and prevalence of CAM amongst an Australian regional radiotherapy patient cohort and the disclosure of information to the consultant radiation oncologist.

Methods

A single hardcopy questionnaire survey was provided to patients regarding the use of CAM and discussion with the treating medical practitioner. The National Centre for Complementary and Alternative Medicine (NCCAM) classification was used to group responses. The study was open for a period of 4 months, and all patients on treatment during this period were approached.

Results

A total of 170 questionnaires were distributed to eligible patients, and 152 patients returned a completed questionnaire (89.4 % response rate). Sixty-nine of the 152 patients (45.4 %) reported active CAM use. Of the 69 patients who used CAM, mind–body medicine (n = 54, 78.3 %) and biological-based therapies (n = 54, 78.3 %) were the commonest NCCAM group, whilst manipulative/body-based therapies (n = 44, 63.8 %), whole medical systems (n = 7, 10.1 %) and energy therapies (n = 5, 7.2 %) were the least common. The most common therapies were vitamins and mineral supplementation (n = 33, 47.8 %) and massage therapy (n = 18, 26.1 %). Of note, only 29 participants stated that they had discussed CAM therapies with their radiation oncologist.

Conclusions

CAM use was prevalent amongst cancer patients undergoing radiotherapy, but frequently not discussed with the treating radiation oncologist. Considering the high prevalence of CAM, further resources could be justifiably directed at providing this service for cancer patients to foster a more holistic approach to their care.

National Institute of Health, National Centre for Complementary and Alternative Medicine. What is Complementary and Alternative Medicine. Available from:-http://nccam.nih.gov/health/whatiscam; Accessed 26th October 2013

Wieland LS, Manheimer E, Berman BM (2011) Development and classification of an operational definition of complementary and alternative medicine for the Cochrane collaboration. Altern Ther Health Med 17(2):50–59PubMedCentralPubMed

Xue CC, Zhang AL, Lin V, Da Costa C, Story DF (2007) Complementary and alternative medicine use in Australia: a national population-based survey. J Altern Complement Med 13(6):643–650. doi:10.1089/acm.2006.6355 PubMedCrossRef

Shorofi SA, Arbon P (2010) Complementary and alternative medicine (CAM) among hospitalised patients: an Australian study. Complement Ther Clin Pract 16(2):86–91. doi:10.1016/j.ctcp.2009.09.009 PubMedCrossRef

Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol Off J Am Soc Clin Oncol 18(13):2505–2514

Pud D, Kaner E, Morag A, Ben-Ami S, Yaffe A (2005) Use of complementary and alternative medicine among cancer patients in Israel. Eur J Oncol Nurs 9(2):124–130. doi:10.1016/j.ejon.2005.03.011 PubMedCrossRef

Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T, Takashima S (2005) Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol Off J Am Soc Clin Oncol 23(12):2645–2654. doi:10.1200/JCO.2005.04.126 CrossRef

Scott JA, Kearney N, Hummerston S, Molassiotis A (2005) Use of complementary and alternative medicine in patients with cancer: a UK survey. Eur J Oncol Nurs 9(2):131–137. doi:10.1016/j.ejon.2005.03.012 PubMedCrossRef

Afifi FU, Wazaify M, Jabr M, Treish E (2010) The use of herbal preparations as complementary and alternative medicine (CAM) in a sample of patients with cancer in Jordan. Complement Ther Clin Pract 16(4):208–212. doi:10.1016/j.ctcp.2010.05.001 PubMedCrossRef

10.

Lifshitz DA, Shikanov SA, Razmaria AA, Eggener SE, Liao C, Chang A, Shalhav AL (2011) Clinical and histologic predictors of renal function decline after laparoscopic partial nephrectomy. J Endourol Endourological Soc 25(9):1435–1441. doi:10.1089/end.2010.0646 CrossRef

11.

Klafke N, Eliott JA, Wittert GA, Olver IN (2012) Prevalence and predictors of complementary and alternative medicine (CAM) use by men in Australian cancer outpatient services. Ann Oncol 23(6):1571–1578. doi:10.1093/annonc/mdr521 PubMedCrossRef

12.

Field KM, Jenkins MA, Friedlander ML, McKinley JM, Price MA, Weideman P, Keogh LA, McLachlan SA, Lindeman GJ, Hopper JL, Butow PN, Phillips KA (2009) Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer. Eur J Cancer 45(4):551–560. doi:10.1016/j.ejca.2008.09.023 PubMedCrossRef

13.

Pedersen CG, Christensen S, Jensen AB, Zachariae R (2009) Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 45(18):3172–3181. doi:10.1016/j.ejca.2009.09.005 PubMedCrossRef

14.

Kao GD, Devine P (2000) Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88(3):615–619. doi:10.1002/(SICI)1097-0142(20000201)88:3<615::AID-CNCR18>3.0.CO;2-P PubMedCrossRef

15.

Swarup AB, Barrett W, Jazieh AR (2006) The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol 29(5):468–473. doi:10.1097/01.coc.0000221326.64636.b2 PubMedCrossRef

16.

Micke O, Bruns F, Glatzel M, Schönekaes K, Micke P, Mücke R, Büntzel J (2009) Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med 1(1):19–25CrossRef

17.

Wong LC, Chan E, Tay S, Lee KM, Back M (2010) Complementary and alternative medicine practices among Asian radiotherapy patients. Asia Pac J Clin Oncol 6(4):357–363PubMedCrossRef

18.

Wong J, Bolderston A (2007) A descriptive study of departmental policies regarding patients use of complementary and alternative medicine in Ontario radiation therapy centres. Can J Med Radiat Technol 38(1):32–38CrossRef

19.

Bolderston A, Mitchell F, Cowan B, Mawson C (2008) Radiation therapists’ experiences with complementary alternative medicine use by their patients: a preliminary study. J Med Imaging Rad Sci 39:128–134CrossRef

20.

Baum M, Ernst E, Lejeune S, Horneber M (2006) Role of complementary and alternative medicine in the care of patients with breast cancer: report of the European Society of Mastology (EUSOMA) Workshop, Florence, Italy, December 2004. Eur J Cancer 42(12):1702–1710. doi:10.1016/j.ejca.2006.02.020 PubMedCrossRef

21.

Pirri C (2011) Integrating complementary and conventional medicine. Cancer Forum 35(1):1–9

22.

Rausch SM, Winegardner F, Kruk KM, Phatak V, Wahner-Roedler DL, Bauer B, Vincent A (2011) Complementary and alternative medicine: use and disclosure in radiation oncology community practice. Support Care Cancer 19(4):521–529PubMedCrossRef

23.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, and Collins SP (2013) Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 8: p. 58. DOI: 10.1186/1748-717X-8-58

24.

Robotin MC, Penman AG (2006) Integrating complementary therapies into mainstream cancer care: which way forward? Med J Aust 185(7):377–379PubMed

25.

Hollenberg D, Cowan B, Wright N (2008) New and uncharted territory: integrative medicine in the medical radiation sciences. Can J Med Rad Technol 38(4):23–30CrossRef

26.

Thomas J, Beinhorn C, Norton D, Richardson M, Sumler SS, Frenkel M (2010) Managing radiation therapy side effects with complementary medicine. J Soc Integr Oncol 8(2):65–80PubMed

27.

Aksu MG, Bozcuk HS, Korcum AF (2008) Effect of complementary and alternative medicine during radiotherapy on radiation toxicity. Support Care Cancer 16(4):415–419. doi:10.1007/s00520-007-0390-0 PubMedCrossRef

Title: Complementary and alternative medicine use and disclosure amongst Australian radiotherapy patients
Authors: Darren Hunter
Richard Oates
Janet Gawthrop
Michelle Bishop
Suki Gill
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 6/2014
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2120-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2014

Distribution of oral mucosal bacteria with mecA in patients undergoing hematopoietic cell transplantation

Metastatic epidural spinal cord compression among elderly patients with advanced prostate cancer

Screening for malnutrition in lung cancer patients undergoing radiotherapy

Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant

Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore

Incidence, predictive factors, and prognosis for winged scapula in breast cancer patients after axillary dissection

Keynote webinar | Spotlight on antibody–drug conjugates in cancer